134 related articles for article (PubMed ID: 10365140)
1. Renal cell carcinoma: relevance of angiogenetic factors.
Wechsel HW; Bichler KH; Feil G; Loeser W; Lahme S; Petri E
Anticancer Res; 1999; 19(2C):1537-40. PubMed ID: 10365140
[TBL] [Abstract][Full Text] [Related]
2. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
[TBL] [Abstract][Full Text] [Related]
3. Angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) are not necessarily elevated in patients with advanced renal cell carcinoma.
Edgren M; Lennernäs B; Larsson A; Kälkner KM
Anticancer Res; 2001; 21(2B):1423-9. PubMed ID: 11396226
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma.
Alamdari FI; Rasmuson T; Grankvist K; Ljungberg B
Scand J Urol Nephrol; 2007; 41(1):5-9. PubMed ID: 17366095
[TBL] [Abstract][Full Text] [Related]
5. Serologic angiogenesis factors and microvascular density in renal cell carcinoma: two independent parameters.
Wechsel HW; Feil G; Bichler KH; Beiter T; Gleichmann R
Anticancer Res; 2000; 20(6D):5117-20. PubMed ID: 11326680
[TBL] [Abstract][Full Text] [Related]
6. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma.
Jacobsen J; Rasmuson T; Grankvist K; Ljungberg B
J Urol; 2000 Jan; 163(1):343-7. PubMed ID: 10604387
[TBL] [Abstract][Full Text] [Related]
9. Angiogenic protein expression in advanced epithelial ovarian cancer.
Barton DP; Cai A; Wendt K; Young M; Gamero A; De Cesare S
Clin Cancer Res; 1997 Sep; 3(9):1579-86. PubMed ID: 9815846
[TBL] [Abstract][Full Text] [Related]
10. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients.
Brattström D; Bergqvist M; Larsson A; Holmertz J; Hesselius P; Rosenberg L; Brodin O; Wagenius G
Anticancer Res; 1998; 18(2A):1123-7. PubMed ID: 9615776
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter.
Inoue K; Kamada M; Slaton JW; Fukata S; Yoshikawa C; Tamboli P; Dinney CP; Shuin T
Clin Cancer Res; 2002 Jun; 8(6):1863-70. PubMed ID: 12060629
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group.
Schips L; Dalpiaz O; Lipsky K; Langner C; Rehak P; Puerstner P; Pummer K; Zigeuner R
Eur Urol; 2007 Jan; 51(1):168-73; discussion 174. PubMed ID: 16844285
[TBL] [Abstract][Full Text] [Related]
13. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?
Tabone MD; Landman-Parker J; Arcil B; Coudert MC; Gerota I; Benbunan M; Leverger G; Dosquet C
Clin Cancer Res; 2001 Mar; 7(3):538-43. PubMed ID: 11297245
[TBL] [Abstract][Full Text] [Related]
14. Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas.
Edgren M; Lennernäs B; Larsson A; Nilsson S
Anticancer Res; 1999; 19(1B):869-73. PubMed ID: 10216508
[TBL] [Abstract][Full Text] [Related]
15. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer.
Feldman AL; Tamarkin L; Paciotti GF; Simpson BW; Linehan WM; Yang JC; Fogler WE; Turner EM; Alexander HR; Libutti SK
Clin Cancer Res; 2000 Dec; 6(12):4628-34. PubMed ID: 11156212
[TBL] [Abstract][Full Text] [Related]
16. Serum angiogenic activity: diagnostic relevance in renal cell carcinoma.
Beecken WD; Bentas W; Glienke W; Linneweber J; Jonas D; Binder J; Kramer W
Eur Urol; 2002 Oct; 42(4):364-9. PubMed ID: 12361902
[TBL] [Abstract][Full Text] [Related]
17. [Determination of vascular endothelial growth factor (VEGF) concentration in serum of patients with colorectal carcinoma].
Broll R; Erdmann H; Windhövel U; Duchrow M; Strik MW
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):315-8. PubMed ID: 14518267
[TBL] [Abstract][Full Text] [Related]
18. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Aguayo A; Kantarjian HM; Estey EH; Giles FJ; Verstovsek S; Manshouri T; Gidel C; O'Brien S; Keating MJ; Albitar M
Cancer; 2002 Nov; 95(9):1923-30. PubMed ID: 12404286
[TBL] [Abstract][Full Text] [Related]
19. Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma.
Shang ZJ; Li JR; Li ZB
Int J Oral Maxillofac Surg; 2002 Oct; 31(5):495-8. PubMed ID: 12418564
[TBL] [Abstract][Full Text] [Related]
20. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group.
Werther K; Christensen IJ; Brünner N; Nielsen HJ
Eur J Surg Oncol; 2000 Nov; 26(7):657-62. PubMed ID: 11078612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
